Ledger.Open graph →
SEC Form D · filed August 12, 2025

Kestrel Therapeutics Inc

Offering
$10.0M
Sold
$5.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
Boston, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (18)

Denis G. Patrick · Boston, MADirectorNicholas G. Saccomano · Boston, MADirectorBarbara G. Sosnowski · Boston, MADirectorFrank G. Haluska · Boston, MAExec · DirectorAndrew G. Phillips · Boston, MADirectorOmar G. Khalil · Boston, MADirectorNicholas G. Saccomano · Boston, MADirectorBarbara G. Sosnowski · Boston, MADirectorOmar G. Khalil · Boston, MADirectorDenis G. Patrick · Boston, MADirectorFrank G. Haluska · Boston, MAExec · DirectorAndrew G. Phillips · Boston, MADirectorFred D. Clark · Fern Park, FLDirectorAaron Dillon · NEW YORK, NYDirectorDavid Barker · Fern Park, FLExec · DirectorRichard Ungaro · Fern Park, FLDirectorHarrison L. Hodges · Fern Park, FLDirectorChad L. Mcghee · Fern Park, FLDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗